The HDDC2 Knockout SK-HEP-1 Polyclonal Cells are a genetically engineered cell population derived from the SK-HEP-1 cell line, generated through CRISPR/Cas9-mediated disruption of the HDDC2 gene. This polyclonal knockout product provides a heterogeneous pool of edited cells with targeted loss-of-function of HDDC2, suitable for studies requiring genetic ablation of this negative regulator. The cells are supplied as a ready-to-use polyclonal culture, bypassing clonal isolation steps and maintaining population diversity.
The parental SK-HEP-1 cell line originates from a human liver adenocarcinoma and exhibits hepatic endothelial-like characteristics, making it a widely used model for liver sinusoidal endothelial function and hepatic tumorigenesis. These cells endogenously express key components of innate immune signaling pathways, including RIG-I, cGAS, and downstream adaptors, which are relevant for studying antiviral immunity and inflammation in the liver microenvironment.
HDDC2 functions as a critical negative regulator of type I interferon (IFN) responses by promoting the ubiquitination and proteasomal degradation of IRF3, a master transcription factor governing IFN-?? and interferon-stimulated gene (ISG) expression. In unperturbed cells, HDDC2 interacts with IRF3 and the ubiquitin-proteasome system to suppress basal and stimulus-induced IRF3 activity. Activation of pattern recognition receptors such as RIG-I by viral nucleic acids or cGAS by cytosolic DNA triggers a signaling cascade involving MAVS, TBK1, and IRF3 phosphorylation; HDDC2 counteracts this by targeting IRF3 for degradation, thereby dampening downstream IFN-?? production and ISG induction. Consequently, HDDC2 knockout leads to IRF3 stabilization, enhanced IFN-?? transcription, and potentiated JAK-STAT signaling through IFNAR-STAT1/STAT2/IRF9 complexes.
In the SK-HEP-1 liver endothelial cell context, disruption of HDDC2 is anticipated to augment innate immune responses, providing a valuable tool for dissecting the molecular interplay between liver sinusoidal cells and antiviral or inflammatory stimuli. This model is particularly suited for investigating how negative regulators of IFN signaling impact hepatic immune surveillance, viral clearance, and immune evasion mechanisms in liver cancer. The polyclonal nature of the knockout population allows assessment of heterogeneous cellular responses, mimicking physiological variability.
Researchers can employ this knockout model for a spectrum of experimental applications, including mechanistic studies of RIG-I/MDA5 and cGAS-STING pathways, viral infection assays using Sendai virus or other hepatotropic viruses, and drug target validation for immune modulation. Common readouts include western blotting for HDDC2 and IRF3 protein levels, RT-qPCR for IFN-?? and ISG transcripts, luciferase reporter assays for IFN-?? promoter activity, immunofluorescence to monitor IRF3 nuclear translocation, and flow cytometry for phospho-STAT1. Transcriptomic profiling via RNA-seq can further elucidate global gene expression changes. For further information or technical support, please contact Ascent Research.
